- Home
- SRTS vs CUE Comparison
SRTS vs CUE Comparison
Compare SRTS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- CUE
- Stock Information
- Founded
- SRTS 2010
- CUE 2014
- Country
- SRTS United States
- CUE United States
- Employees
- SRTS N/A
- CUE N/A
- Industry
- SRTS Medical/Dental Instruments
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- CUE Health Care
- Exchange
- SRTS Nasdaq
- CUE Nasdaq
- Market Cap
- SRTS 51.8M
- CUE 59.5M
- IPO Year
- SRTS 2016
- CUE 2018
- Fundamental
- Price
- SRTS $3.15
- CUE $0.73
- Analyst Decision
- SRTS Strong Buy
- CUE Strong Buy
- Analyst Count
- SRTS 3
- CUE 2
- Target Price
- SRTS $8.00
- CUE $3.00
- AVG Volume (30 Days)
- SRTS 84.7K
- CUE 132.9K
- Earning Date
- SRTS 11-13-2025
- CUE 11-13-2025
- Dividend Yield
- SRTS N/A
- CUE N/A
- EPS Growth
- SRTS N/A
- CUE N/A
- EPS
- SRTS N/A
- CUE N/A
- Revenue
- SRTS $37,564,000.00
- CUE $8,286,000.00
- Revenue This Year
- SRTS N/A
- CUE N/A
- Revenue Next Year
- SRTS $46.14
- CUE $13.27
- P/E Ratio
- SRTS N/A
- CUE N/A
- Revenue Growth
- SRTS 3.29
- CUE N/A
- 52 Week Low
- SRTS $3.03
- CUE $0.45
- 52 Week High
- SRTS $9.33
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- SRTS 37.43
- CUE 37.43
- Support Level
- SRTS $3.09
- CUE $0.71
- Resistance Level
- SRTS $3.29
- CUE $0.78
- Average True Range (ATR)
- SRTS 0.11
- CUE 0.03
- MACD
- SRTS 0.04
- CUE -0.01
- Stochastic Oscillator
- SRTS 15.38
- CUE 20.10
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.